NASDAQ: LMAT · Medical Instruments & Supplies
LeMaitre Vascular (LMAT) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values LeMaitre Vascular (LMAT) at $93.66 a share. The stock last closed at $77.01, which puts the model's fair value 21.6% above the price. On the model's bands that reads as Undervalued.
Revalued . Price is the close of 16 Nov 2026. LeMaitre Vascular, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $74.73 to $93.66 (+25.3%). The model changed its method this week; the move is not broken down.
What the model makes of itThe price of $77.01 is 21.6% below it: Undervalued, on a medium evidence grade.
What's nextNext report on 24 Feb 2027. Options prices imply a move of about 11% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give LMAT?
The calibrated range for LMAT over 63 trading days is $67.70 to $88.17. It sits around the last close, and its width comes from the volatility that LMAT's own options imply (39% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $62.09 to $136.00. In 64% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
LeMaitre Vascular, Inc. (LMAT) operates worldwide, developing, distributing and maintaining medical devices and implants for treating peripheral vascular disease. It sits in the healthcare sector, within medical instruments and supplies.
Faircurve's model put the fair value at $93.66 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $74.73, so the fair value moved +25.3%. The model changed its method this week; the move is not broken down. The calibrated range over 63 trading days is $67.70 to $88.17. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium. The grade covers input completeness, comparable companies and the width of outcomes. It does not say whether the fair value is right.
The model's overall quality score is 68 out of 100, a composite of six factors scored against comparable companies. Profitability stands out at 79, with ROIC of 9.7% against a peer median of -0.8%. Stability scores 64, with five-year EBITDA margin downside volatility of 3.3 pts against a peer median of 5.8 pts. The comparison set includes DENTSPLY SIRONA Inc. (XRAY), ICU Medical, Inc. (ICUI) and Teleflex Incorporated (TFX), among others.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does LMAT report earnings, and how has the stock reacted?
LeMaitre Vascular's next earnings report is scheduled for 24 Feb 2027. Companies can move their dates.
On 16 Nov 2026, LMAT's 30 day implied volatility worked out to a move of about 11.3% over one month, in either direction. That is a size, not a direction.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across LMAT's last 8 reports, ignoring direction, was 9.3%.
How does LMAT score on business quality?
LeMaitre Vascular's overall quality score is 68 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 79 | 9.7%ROIC | -0.8% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 66 | 1.06xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 60 | 13.5%Revenue growth, trailing | 14.2% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 72 | 0.0%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 56 | 1.76xNet debt / EBITDA | |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 64 | 3.3 ptsEBITDA margin downside volatility, 5y | 5.8 pts |
How does LMAT compare with similar companies?
The companies in medical instruments & supplies closest to LeMaitre Vascular in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| XRAY DENTSPLY SIRONA Inc. | $8.95 | $13.35 | +49.2% | Undervalued |
| STAA STAAR Surgical Company | $26.01 | $24.60 | -5.4% | Fairly valued |
| NVST Envista Holdings Corp | $24.03 | $25.54 | +6.3% | Low evidence grade |
| ICUI ICU Medical, Inc. | $181.87 | $202.62 | +11.4% | Fairly valued |
| MMSI Merit Medical Systems, Inc. | $86.35 | $82.63 | -4.3% | Fairly valued |
| TFX Teleflex Incorporated | $157.10 | $169.00 | +7.6% | Fairly valued |
| EMBC Embecta Corp. | $6.25 | $7.68 | +22.9% | Low evidence grade |
| ATR AptarGroup, Inc. | $143.17 | $137.10 | -4.2% | Fairly valued |
What the comparable companies' multiples alone would give for LMAT, the peer-implied price, is $196.79 a share on this run. The fair value weighs that against the company's own multiple.
All medical instruments & supplies stocks ranked by gap to fair value
LeMaitre Vascular at a glance
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease.
- Market value
- $1.8B
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Revenue expected, next twelve months
- $300M
- Consensus revenue growth, next fiscal year
- +10.6%
- Analysts with estimates
- 6
- Beta to the US market
- 0.47
- First valued by Faircurve
- 11 Jul 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. LMAT was among them.
How the fair value is worked out: the model prices LeMaitre Vascular on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for LMAT was $74.73. As of 14 Nov 2026 it is $93.66, a change of +25.3%. The model changed its method this week; the move is not broken down. The model revalues every stock it covers each week, and again after an earnings report.
Questions about LeMaitre Vascular's valuation
Is LeMaitre Vascular stock undervalued or overvalued?
On Faircurve's model, LMAT reads as Undervalued as of 14 Nov 2026. The model's fair value is $93.66 a share against a last close of $77.01, a gap of +21.6%.
What is LMAT's fair value?
$93.66 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $62.09 to $136.00.
What price range does the model give LMAT?
$67.70 to $88.17 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does LeMaitre Vascular report earnings next?
The next report is scheduled for 24 Feb 2027. Companies can move their dates.
How much has LMAT moved on past earnings reports?
Across its last 8 reports the median two session move was 9.3%, ignoring direction. The largest was +25.3% around the report of 25 Feb 2026.
How confident is the model in this valuation?
The model's evidence grade for LMAT is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on LMAT
The model holds no idea open on LMAT today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on LMAT with their outcomes. A free account is enough.